ABCELY

📍 Nantes, France🗓 Founded 2022👥 5 employees💰 Last funded Jul 2023
Biotechnology Research
LinkedIn
Abcelys mission is to revolutionize the treatment of mucosal cancers, endometriosis, and inflammatory bowel diseases by pioneering innovative medical and pharmaceutical technologies. With a focus on providing new hope for patients facing therapeutic dead ends, Abcely introduces a groundbreaking concept in immunotherapy. At the heart of this innovation is the use of a novel class of orally active therapeutic molecules: class A immunoglobulins (sIgA). Abcely is committed to advancing these treatments through every stage of development—from identifying active compounds to proving their efficacy in human clinical trials—ensuring a transformative impact on patient care.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in ABCELY?
ABCELY has 1 investors on record on gritt.io, including 1 early-stage backers.
When did ABCELY last raise funding?
The most recent investment in ABCELY recorded on gritt.io was in July 2023.
When was ABCELY founded?
ABCELY was founded in 2022.
What industry is ABCELY in?
ABCELY operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is ABCELY based?
ABCELY is headquartered in Nantes, France.